Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

801 - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer


24 Nov 2018


Poster display - Cocktail


Translational Research

Tumour Site

Breast Cancer


Mohamed Elbaiomy


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


M.A. Elbaiomy1, M.S. El-Ghonemy2, R. Elhelaly3, R. Elzehery3

Author affiliations

  • 1 Medical Oncology, Oncology Centre Mansura University, 50 - Dakahlia/EG
  • 2 Clinical Pathology, Oncology Centre Mansura University, 50 - Dakahlia/EG
  • 3 Clinical Pathology, Faculty of Medicin Mansoura University, Dakahlia/EG


Abstract 801


Osteopontin (OSP) is a metastasis-related gene associated with progression cancers. We assigned osteopontin as potential contributors in breast cancer.


115 de novo metastatic breast cancer (MBC) patients presented by visceral with or without bone metastasis (visceral crisis), brain metastasis was excluded. Patients received first line Docetaxel plus cisplatin and anti Her2 (for Her2 positive) whenever governmental or financial support. Serum osteopontin was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.


High serum OSP was observed in Her2 amplified (mean±SD; 64.4±42.3) followed by TNBC (mean ± SD; 55.9 ± 34.7) then Luminal A and B subtypes (mean±SD; 36.3±32.2) and (mean±SD; 38.3±33.1), respectively (P 0.01). By sequencing technique OSP gene mutation was highly presented in TNBC (85% mutant versus 15% OSP non mutant) followed by Her2 amplified (80% mutant versus 20% OSP non mutant) then luminal B (61.9% mutant versus 38.1% OSP non mutant) and luminal A (57.9% mutant versus 42.1% OSP non mutant). High serum lOSP was significantly correlated with disseminated visceral and bone metastasis (P 0.03). Both high serum OSP level and OSP gene mutation showed same poor PFS (median, 12 months vs. 14 months; P = 0.001) and poor OS (median, 14 months vs. 18 months; P = 0.001). Patients with mutant OSP demonstrated poor response (74% of SD & progressed diseases were mutant versus 26% were non mutant OSP, P 0.04). Also, high pretreatment serum OSP level was associated with poor response (mean±SD for stable & progressed diseases was 49.1±33.8 versus 35.5±37.3 for complete &partial responder, P 0.05.Complete concordance was detected between high serum OSP by ELIZA and OSP gene mutation in 69 tumors (79.3%) while, complete concordance between Normal/Low serum OSP by ELIZA and non-mutant OSP was observed in 28 tumors (60.8%).


OSP is a reliable prognostic biomarker for MBC.Concordance between ELIZA and sequencing techniques denoting that any of these methods may be used for osteopontin assessment. Increased OSP mutation in TNBC may help for tailoring treatment in this very aggressive subtype.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

University Hospital.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.